^
    Back
    Association details:
    Biomarker:BAP1 deletion
    Cancer:Renal Cell Carcinoma
    Drug:Lynparza (olaparib) (PARP inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Nat Genet
    Title:

    BAP1 loss defines a new class of renal cell carcinoma

    Excerpt:
    In addition, BAP1 loss sensitized cells to the PARP inhibitor olaparib
    DOI:
    10.1038/ng.2323